US 11028160
Treating refractory migraine
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 11028160 (Treating refractory migraine) held by TEVA PHARMACEUTICALS INTERNATIONAL GMBH expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- TEVA PHARMACEUTICALS INTERNATIONAL GMBH
- Grant date
- Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K39/3955